Published in Med Care on March 01, 2008
Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiol Drug Saf (2012) 1.20
Treatment outcomes in elderly with advanced-stage non-small cell lung cancer. Lung (2013) 0.84
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol (2016) 0.83
Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data. J Oncol Pract (2014) 0.83
Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). J Geriatr Oncol (2014) 0.76
Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. PLoS One (2015) 0.75
Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer (2017) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy? J Clin Oncol (2007) 5.14
Utility of the SEER-Medicare data to identify chemotherapy use. Med Care (2002) 5.07
Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol (2003) 4.77
Medicare's common denominator: the covered population. Health Care Financ Rev (1980) 4.37
Use of SEER-Medicare data for measuring cancer surgery. Med Care (2002) 4.27
Studying radiation therapy using SEER-Medicare-linked data. Med Care (2002) 4.13
Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst (2001) 3.65
Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making (2001) 2.54
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol (2002) 2.09
Representation of older patients in cancer treatment trials. Cancer (1994) 2.06
Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care (2002) 1.87
External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care (2006) 1.74
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst (2005) 1.70
Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control (2006) 1.06
Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health (2005) 0.84
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Dynamic spread of happiness in a large social network: longitudinal analysis over 20 years in the Framingham Heart Study. BMJ (2008) 10.80
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Model of genetic variation in human social networks. Proc Natl Acad Sci U S A (2009) 8.73
Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol (2004) 7.45
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Cooperative behavior cascades in human social networks. Proc Natl Acad Sci U S A (2010) 5.00
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol (2006) 4.91
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
Dynamic social networks promote cooperation in experiments with humans. Proc Natl Acad Sci U S A (2011) 4.58
Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol (2003) 4.50
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol (2007) 4.42
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
The spread of alcohol consumption behavior in a large social network. Ann Intern Med (2010) 4.02
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
A dynamic network approach for the study of human phenotypes. PLoS Comput Biol (2009) 3.62
Social networks and cooperation in hunter-gatherers. Nature (2012) 3.59
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol (2006) 3.50
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA (2005) 3.43
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Social networks and collateral health effects. BMJ (2004) 3.08
Geographic constraints on social network groups. PLoS One (2011) 3.08
Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet (2010) 3.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". JAMA (2003) 2.98
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol (2010) 2.97
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol (2006) 2.87
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care (2005) 2.75
Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst (2002) 2.71
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Variation in patient-sharing networks of physicians across the United States. JAMA (2012) 2.59
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46
Self-perception of weight appropriateness in the United States. Am J Prev Med (2003) 2.41
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Alone in the crowd: the structure and spread of loneliness in a large social network. J Pers Soc Psychol (2009) 2.33
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg (2006) 2.29
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
The impact of cellular networks on disease comorbidity. Mol Syst Biol (2009) 2.23
Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care (2013) 2.22
Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation. Radiology (2004) 2.21
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol (2007) 2.20
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol (2013) 2.20
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res (2005) 2.19
Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. J Clin Oncol (2004) 2.18
Patients' experiences with care for lung cancer and colorectal cancer: findings from the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2010) 2.16
On the prospects for a blame-free medical culture. Soc Sci Med (2009) 2.16
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Parents' views of cancer-directed therapy for children with no realistic chance for cure. J Clin Oncol (2008) 2.12
Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst (2003) 2.11
Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research. Palliat Med (2006) 2.11
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08